Ranbaxy ties up with UK firm to market its cancer pill
NEW DELHI: Brian Tempest, Ranbaxy pharmaceutical president, said, "We will continue to provide novel products for Indian customers and believe that TransMID will help us strengthen our position in the high value oncology segment,"
Dr Steven Powell, CEO of K S Biomedix, said, "This latest agreement is the fourth territory licensed for TransMID this year, extending the commercial coverage for the product significantly."
Post your Comment
All form fields are required.